Diabetic nephropathy
Conditions
Interventions
No randomization group: with/without use ACEI/ARB history:Taking dapagliflozin or ARB
Randomization group 1: without use ACEI/ARB history:Basal treatment for the blood sugar control + oral Daglitel tablets 10mg for 24 weeks
Randomization group 2: Without use ACEI/ARB history group 2:Basal treatment for the blood sugar control + oral Irbesartan tablets 10mg for 24 weeks
Sponsors
Huaian First People's Hospital
Eligibility
Sex/Gender
All
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Know the content of the informed consent before any special operation; 2. Men or women aged 25 to 75 years old; 3. Patients with type 2 diabetes (in line with WHO standards); 4. Glycated hemoglobin 6.5 to 12.0 %; 5. Combined albuminuria (UACR 30 to 2500mg/g, eGFR >=45 ml/min/1.73m2).
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes; 2. Other secondary kidney diseases other than diabetes; 3. Known or suspected allergies to the test drugs and similar products; 5. Severe cardiovascular and cerebrovascular diseases; 6. Severe liver and kidney dysfunction; 7. A history of kidney dialysis and kidney transplantation; 8. Being breastfeeding; 9. Those who are pregnant or have a positive pregnancy test at the time of screening, or who are unwilling to take full contraception (contraception methods include sterilization, intrauterine birth control, oral contraceptives, physical contraception); 10. Received systemic corticosteroid treatment within 2 months before screening; 11. Patients with SGLT2i, pioglitazone, GLP-1 receptor agonist, and DPP-IV inhibitors (adjusted in advance) within 3 months; 12. Received any trial drug within 1 month before participating in this research project.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine protein level, eGFR, renal function; | — |
Countries
China
Contacts
Public ContactZhang Hong
Huaian First People's Hospital
Outcome results
None listed